Search results
Added:
1 year ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical…
View more
Added:
10 months ago
Discover the sex-specific challenges in aortic stenosis diagnosis and management with Prof Nicole Karam (European Hospital Georges Pompidou, Paris, FR).This presentation, part of a comprehensive two-part series on complex cases in interventional cardiology, explores the critical pathophysiological differences between men and women that impact diagnostic approaches and therapeutic decision-making…
View more
Added:
8 months ago
Explore comprehensive lifetime management strategies for aortic stenosis with Dr Samineh Sehatbakhsh, addressing the evolving landscape of treatment options for patients across all risk categories.This detailed presentation, part of the Complex Cases track, examines the critical decision-making process between TAVR and surgical aortic valve replacement in the modern era. Dr Sehatbakhsh addresses…
View more
Added:
1 year ago
EuroPCR 24 - We are joined onsite by Prof Ole De Backer (Rigshospitalet, DK) to discuss the findings from the NOTION-2 Study. (NCT02825134).NOTION-2 is a randomized, multicenter trial which aimed to investigate transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in 376 patients under 75 years of age with severe aortic valve stenosis in regard to intra-…
View more
Start date:
Jun 25, 2025
Join an expert panel of internationally recognised cardiovascular specialists for a CME-accredited* webinar on the latest strategies in hypertension management for patients with cardiovascular disease. Chaired by Dr Yassir Javaid (Imperial College Healthcare NHS Trust, London, UK), with Prof Michel Burnier (University Hospital of Lausanne, Lausanne, CH) Prof Mariya Tokmakova (Medical University…
View more
Added:
2 months ago
Source:
Transcatheter Academy
Seven-year follow-up data from the PARTNER 3 trial shows no significant difference in key outcomes between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This long-term assessment provides further insight into valve durability and clinical outcomes, building on previous 5-year data which…
View more
Prasad Gunasekaran
Research Area(s) / Expertise:
Job title: Interventional Cardiologist
Author
Added:
1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of transcatheter aortic valve replacement (TAVR) in addition to optimal heart failure therapy (OHFT) compared to OHFT alone in patients with heart failure and moderate aortic stenosis.Dr Nicolas M Van Mieghem (Erasmus University Medical Center, Rotterdam, NL) joins us onsite at TCT Conference to discuss the findings from TAVR UNLOAD (NCT02661451)…
View more
Added:
2 months ago
Source:
Cardiac Failure Review
Single-pill low-dose combination (LDC) therapy is an emerging strategy for improving blood pressure (BP) control in patients with hypertension.¹ Two new phase III trials, HM-APOLLO-301 and HM-APOLLO-302, have evaluated the efficacy and safety of an ultra-low-dose triple combination pill compared with standard-dose monotherapy as an initial treatment for mild-to-moderate hypertension…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
An exploratory analysis of the EARLY TAVR trial has found that the benefits of early transcatheter aortic valve replacement (TAVR) for asymptomatic severe aortic stenosis (AS) are consistent, regardless of baseline left ventricular (LV) health.¹ This suggests that waiting for LV deterioration may not be the optimal strategy for timing intervention.MethodologyThis analysis used data from the EARLY…
View more